
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova's sales exhibited significant growth of 29%, reaching $803 million in 2024, with management forecasting further sales expansion to between $940 million and $955 million. The positive outlook is bolstered by projected market share increases for the aura6000 device, with potential sales estimates rising substantially from $30 million in 2027 to $280 million by 2029 in an optimistic scenario. Additionally, LivaNova's diversified revenue streams, with approximately half derived from the U.S. market and a strong presence in Europe, contribute to its robust financial foundation and growth potential in the medical-device sector.
Bears say
LivaNova faces a negative outlook due to projected revenue growth slowing to low-single digits, primarily driven by persistent challenges in its Neuromodulation and Cardiovascular businesses. Furthermore, the company is experiencing operating margin contraction alongside expectations for below-consensus earnings, exacerbating financial performance concerns. Notably, risks such as potential delays in FDA approval for key products and slower-than-anticipated growth in both Neuromodulation and Cardiopulmonary sectors contribute to the overall bearish sentiment regarding the stock.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares